Chemistry:PH10 (drug)
From HandWiki
 | |
| Clinical data | |
|---|---|
| Other names | PH10A; PH10 NS[1] |
| Routes of administration | Intranasal |
| Legal status | |
| Legal status |
|
PH10 is a purported vomeropherine that is under development by VistaGen Therapeutics as a nasal spray for the treatment of major depressive disorder.[2][3][4][5]
See also
References
- ↑ "PH-10 Nasal Spray". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800043336.
- ↑ "VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study :: VistaGen Therapeutics, Inc. (VTGN)" (in en). https://www.vistagen.com/news-media/press-releases/detail/100/vistagen-therapeutics-acquires-worldwide-rights-to-develop.
- ↑ "Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more". San Francisco Business Times. October 29, 2018. https://www.bizjournals.com/sanfrancisco/news/2018/10/29/depression-ketamine-vistagen-vtgn-gilead-taxes.html.
- ↑ PH 10 may be a new rapidly acting intranasally administered antidepressant. American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, FL. 2013.
- ↑ Jancin, Bruce (2013). "Novel intranasal antidepressant shows results after 1 week". Clinical Psychiatry News. http://www.clinicalpsychiatrynews.com/specialty-focus/depression/single-article-page/novel-intranasal-antidepressant-shows-results-after-1-week/f88c1d176634f223babe0169c6f4af2f.html. Retrieved 13 January 2016.
 |
